Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Tuesday's Analyst Blog:

Regeneron Outlook Optimistic

Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) lead candidates are VEGF-Trap for the treatment of cancers, eye diseases, and IL-1 Trap for CAPS, a rare genetic disorder, and gout. The company recently received the approval from the Food and Drug Administration on Arcalyst for CAPS. It also has a number of pre-clinical drug candidates for other disorders.

The company made impressive progress in recent months in terms of clinical developments and business developments. We maintain our Buy rating on the shares.

We are optimistic about the company's Trap Technology. The Bayer collaboration on VEGF-Trap-Eye validates this technology and its value for eye diseases. The VEGF-Trap-Cancer programs with Sanofi-Aventis (NYSE: SNY) are progressing very well. We are impressed by the new deal with Sanofi-Aventis to develop antibody drugs. We are also pleased to see the license deals with AstraZeneca (NYSE: AZN) and Astellas to monetize and validate the company's VelocImmune technology.

Ambac Rates a Sell Pre-Earnings

Ambac Financial Group Inc. (NYSE: ABK) expects to release its 2Q08 results on August 6, 2008, with a conference call scheduled the same day. Over the past several days, the shares have reacted positively to the resolution of a $1.4 billion CDO transaction with Citigroup (NYSE: C).

However, the rating agency's current negative outlook, the capital raised dilutive effect on the shareholders equity and earnings, incremental collateral posting, economic pressures enhancement of the housing market woes and competitive challenges from writing new business during next several quarters should continue to weigh on ABK's ability to generate revenue and EPS over the near term.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Story Source: Business Wire